Preimplantation Genetic Testing

Preimplantation Genetic Testing

Global Preimplantation Genetic Testing Market to Reach US$1.5 Billion by 2030

The global market for Preimplantation Genetic Testing estimated at US$768.0 Million in the year 2023, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 9.9% over the analysis period 2023-2030. Reagents & Consumables Component, one of the segments analyzed in the report, is expected to record a 10.6% CAGR and reach US$794.1 Million by the end of the analysis period. Growth in the Instruments Component segment is estimated at 8.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$212.5 Million While China is Forecast to Grow at 9.3% CAGR

The Preimplantation Genetic Testing market in the U.S. is estimated at US$212.5 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$226.9 Million by the year 2030 trailing a CAGR of 9.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.3% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Global Preimplantation Genetic Testing Market – Key Trends & Drivers Summarized

How Is the Rising Demand for Assisted Reproductive Technologies Shaping the Preimplantation Genetic Testing Market?

The preimplantation genetic testing (PGT) market is undergoing significant growth, largely driven by the increasing demand for assisted reproductive technologies (ART) such as in vitro fertilization (IVF). As infertility rates rise globally, more couples are seeking advanced reproductive options to achieve pregnancy, leading to an uptick in the utilization of PGT. This testing allows for the screening of embryos for specific genetic conditions before implantation, thereby enhancing the chances of a successful pregnancy and reducing the risk of genetic disorders. The integration of PGT into IVF procedures has become a standard practice, significantly influencing the decision-making process for couples undergoing ART. With the advancements in genetic testing technologies, PGT has evolved to offer more accurate and comprehensive screening for a wide range of genetic disorders, including chromosomal abnormalities, single-gene disorders, and aneuploidies.

Moreover, the increasing awareness and acceptance of genetic testing in the general population are contributing to the growth of the PGT market. Educational campaigns and the availability of information regarding the benefits of genetic testing have empowered prospective parents to make informed decisions about their reproductive health. This trend is particularly pronounced among older parents who may be more concerned about the genetic health of their children due to advanced maternal age. The demand for PGT is also fueled by the increasing number of fertility clinics offering these services, making PGT more accessible to couples who may have previously been unaware of their options. As consumer confidence in genetic testing grows, so does the market for preimplantation genetic testing.

What Role Do Technological Advancements Play in the Evolution of Preimplantation Genetic Testing?

Technological advancements are playing a crucial role in transforming the PGT landscape, enabling more precise and efficient testing methods. The introduction of next-generation sequencing (NGS) technologies has revolutionized genetic testing, allowing for the simultaneous analysis of multiple genes and chromosomes with greater accuracy and speed. NGS facilitates comprehensive preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS), enabling clinicians to identify genetic abnormalities in embryos more effectively. This technology not only enhances the detection rates of genetic disorders but also reduces the time required for testing, which is critical in the time-sensitive context of embryo selection during IVF cycles.

Furthermore, advancements in embryo culture techniques and the development of time-lapse imaging technologies have improved embryo assessment, enabling embryologists to monitor embryo development in real time. These innovations allow for better selection of viable embryos, thus optimizing the chances of successful implantation and pregnancy. As the technology continues to evolve, it is anticipated that PGT will become increasingly integrated with automated systems that enhance laboratory workflows and reduce human error. This integration will further streamline the process of genetic testing, making it more efficient and accessible for patients.

How Are Changing Consumer Preferences Influencing the Preimplantation Genetic Testing Market?

Changing consumer preferences towards personalized healthcare are significantly influencing the demand for PGT services. As awareness about genetic health increases, individuals and couples are more inclined to seek options that align with their personal health goals and reproductive plans. The trend towards personalized medicine has led to a greater acceptance of genetic testing, as consumers view PGT not only as a preventive measure against hereditary diseases but also as a means to tailor their reproductive choices. This shift is particularly evident among millennials and Gen Z consumers, who prioritize health and wellness and are proactive about managing their genetic health.

Additionally, the desire for family planning and the growing trend of delayed parenthood among younger generations further drive the demand for PGT. As individuals prioritize career and personal development, they often seek reproductive technologies that can help mitigate the risks associated with advanced maternal age, including chromosomal abnormalities. This trend has led to a growing acceptance of genetic testing as a routine part of the fertility journey, with many prospective parents considering PGT an essential step in the IVF process. As a result, fertility clinics are increasingly offering PGT as a standard component of their services to meet the evolving expectations of their patients.

What Factors Are Driving Growth in the Preimplantation Genetic Testing Market?

The growth in the preimplantation genetic testing (PGT) market is driven by several factors, including advancements in genetic testing technologies, increasing infertility rates, and rising consumer awareness of genetic health. The evolution of next-generation sequencing (NGS) and other innovative technologies has significantly improved the accuracy and efficiency of PGT, making it a preferred choice for many prospective parents undergoing assisted reproductive technologies. Additionally, the growing prevalence of infertility and the demand for ART solutions have expanded the addressable market for PGT, as couples seek to enhance their chances of a successful pregnancy.

Moreover, changing consumer behaviors towards personalized health and wellness are contributing to the increased adoption of PGT. As more individuals become informed about their genetic health options, there is a rising expectation for tailored reproductive services that align with their specific health goals. The integration of PGT into standard IVF practices is further fueled by the increasing number of fertility clinics offering these services, making them more accessible to a broader population. Regulatory support for genetic testing and advancements in healthcare policies also play a significant role in promoting the adoption of PGT. Together, these factors create a robust growth environment for the preimplantation genetic testing market, positioning it as a critical component of modern reproductive health care.

SCOPE OF STUDY:

The report analyzes the Preimplantation Genetic Testing market in terms of US$ Thousand by the following Component; End-Use; Technology, and Geographic Regions/Countries:

Segments:
Component (Reagents & Consumables, Instruments, Software & Services); Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In-Situ Hybridization (FISH), Other Technologies); End-Use (Maternity Centers & Fertility Clinics, Hospitals, Diagnostic Labs & Service Providers, Research Laboratories & Academic Institutes)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

• Ariosa Diagnostics
• Bioarray S.L.
• California Pacific Medical Center (CPMC)
• CombiMatrix
• CooperSurgical, Inc.
• F. Hoffmann-La Roche Ltd.
• Genea Limited
• Genesis Genetics
• Good Start Genetics, Inc.
• IGENOMIX
• Illumina, Inc.
• Invitae Corporation
• Laboratory Corporation of America Holdings
• Natera, Inc.
• Oxford Gene Technology
• PerkinElmer Inc.
• Quest Diagnostics Incorporated
• Reproductive Genetic Innovations, LLC
• Reprogenetics
• RHS Ltd.
• Sequenom
• Thermo Fisher Scientific, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.